Cabenuva® (cabotegravir and rilpivirine extendedrelease injectable suspension)

Covered: Cabenuva is covered as a complete regimen to replace a current antiretroviral regimen in adults and adolescents ≥12 years and ≥35 kg who are virologically suppressed (HIV‑1 RNA <50 copies/mL) with no history of treatment failure and no known or suspected resistance to cabotegravir or rilpivirine; it is not covered for viremic patients or those with prior failure/resistance. Key requirements: initial approval requires documentation of age/weight, viral suppression, prior stable ARV ≥3 months or an oral lead‑in with Vocabria per dosing schedule, prescription by or consultation with an HIV specialist, and is authorized for 12 months with reauthorization contingent on maintained viral suppression.

"Must have no history of treatment failure."

Sign up to see full coverage criteria, indications, and limitations.